



## Investigating the Next-Generation of Cancer Therapies

Guest Editors:

**Dr. Gregory F. Alberts**

**Dr. Richard Morgan**

**Dr. Terry Fisher**

**Dr. Ildiko Csiki**

Deadline for manuscript  
submissions:

**closed (5 December 2018)**

### Message from the Guest Editors

Immunotherapy is a term that embodies new hope in the fight against cancer and other diseases, by exploiting the body's own immune system to fight disease, and was recognized by *Science Magazine* as the 2013 “Scientific Breakthrough of the Year”. After years of claiming that this year or that decade represented the “Golden Age of Biotechnology”, and though there have indeed been many notable discoveries and improvements on existing therapies and strategies, we are now on the cusp of implementing new and innovative cancer therapies that in many ways represent the first real return on the investments made in biotechnology over the past decades. From PD-1/PD-L1 antagonists or knockouts to the very latest in CAR-T therapies, there is justifiable optimism for the future of the treatment of cancer; there are myriad ways in which these new ideas can be exploited, some of which will be explored in the course of this issue.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)